<DOC>
	<DOCNO>NCT00361738</DOCNO>
	<brief_summary>Dose-ranging study AVE2268 management patient type 2 diabetes mellitus also receive metformin . Its main objective assess effect several dos AVE2268 Mean Plasma Glucose . Its secondary objective assess effect AVE2268 plasma glucose ( fast post-prandial ) , also safety tolerability AVE2268 .</brief_summary>
	<brief_title>Dose-Ranging Study Evaluating AVE2268 Patients With Type 2 Diabetes Not Adequately Controlled Metformin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus , define American Diabetes Association , least one year time screen . HbA1c measure visit 1 range ≥ 7.0 &lt; 9.0 % . Stable metformin treatment ( dose ≥ 1.5g/day least 3 month prior enrollment study ) . No antidiabetic medication permit 3 month prior enrollment . Pregnant breastfeed woman . Women childbearing potential protect medically approve contraceptive method birth control . BMI &gt; 40kg/m2 Diabetes type 2 diabetes . Subjects `` brittlediabetes '' hospitalization emergency room visit due poor diabetic control within past 6 month , previous history diabetes relate dehydration lead hospitalization , history evidence ketoacidosis . Presence history cancer within past five year . Evidence within past 6 month myocardial infarction , stroke , retinopathy require laser surgery , heart failure require hospitalization . Impaired hepatic test , impair renal function . History evidence clinically relevant renal urological disorder . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>